Stanley Hirsch, D.Phil., has been a member of the company’s board of directors since 2005, and has served as Chairman of the board of Foamix since May, 2016. Dr. Hirsch has 30 years of experience in executive positions across the healthcare, diagnostic, and agricultural/biotech industries. He has extensive executive and board level experience in public and private companies listed on both U.S and U.K exchanges. Dr. Hirsch is currently Group CEO at FuturaGene Ltd., a leading agricultural biotechnology company, where he has held this position since 2007. Prior to this role, Dr. Hirsch was the CEO at CBD Technologies Ltd., the predecessor company to FuturaGene, from 1995 until 2007. Prior executive positions held by Dr. Hirsch include CEO at a diagnostics company GamidaGen, and General Manager at Portman Pharmaceuticals. Dr. Hirsch currently also serves as Chairman of the board of directors of OWC Pharmaceutical Research Corporation (OWCP), and as a board director and member of the Scientific Advisory Board of Biological Industries, a privately held research products company focused on the stem cell industry. Dr. Hirsch holds a D. Phil in Cell Biology and Immunology from Oxford University, England.
Chairman of the Audit Committee and Member of the Compensation Committee
Stanley Stern has been a member of the company’s board of directors and Chairman of the Audit Committee since September 2014. Mr. Stern has over 30 years of experience as an investment banker, holding positions at Salomon Brothers, C.E. Unterberg, STI Ventures, and from 1982 to 1999, and also from 2004 to 2013, at Oppenheimer & Co., serving as Managing Director and Head of Investment Banking, Head of Technology, Israeli Banking and Financial Institutions Groups (FIG). Since February 2013, Mr. Stern has served as the President of Alnitak Capital Partners, a private merchant bank and strategic advisory firm. From 2002 until 2013, Mr. Stern served as a member of the board of directors of Tucows, Inc., a publicly traded internet service provider, including as Chairman of the board from 2002 until 2012. From 2005 until its sale in 2011, he served as a director at Fundtech Ltd., and from 2004 until 2009, Mr. Stern served as a director at Odimo Inc. (DBA Diamond.com), an online jewelry vendor. From 2012 until its sale in 2014, he served as a director at Given Imaging Ltd., a medical device company. Mr. Stern is currently Chairman of the board of directors of Soda Stream and AudioCodes Ltd. In addition, he serves on the board of directors of Ormat Technologies, Inc., Ekso Bionics and Tigo Energy, Inc. Mr. Stern holds an M.B.A. from Harvard Business School and a B.A. from Queens College.
Chairman of the Compensation Committee and Member of the Audit Committee
Rex Bright has been a member of the company’s board of directors and Chairman of the Compensation Committee since September 2014. Mr. Bright is a specialty pharmaceuticals and biotech executive with extensive experience in dermatology. Mr. Bright has spent over 20 years as a startup and turnaround CEO, and most recently founded and served as President & CEO of SkinMedica until it was acquired by Allergan in 2012. Prior to SkinMedica, Mr. Bright was President of Allergan Skincare and spent 19 years at Johnson & Johnson leading their dermatology division, which included the launch of Retin-A. He served on the board of directors of RestorGenex, Inc. through the Company’s merger with Diffusion Pharmaceuticals in 2016. Mr. Bright currently is a member of the board of directors of Clarify Medical and MDRejuvenia. He completed executive programs at Harvard, Stanford and Northwestern University and holds a B.A. degree in Business Administration from Drury University in Springfield, Missouri.
Dr. Anna Kazanchyan
Member of the Compensation Committee
Anna Kazanchyan, M.D. has been a member of the company’s board of directors since December 2014. She is a biotechnology executive with 20 years of experience at Wall Street firms, biopharmaceutical companies and as an entrepreneur. Since September 2016, Dr. Kazanchyan has been the CEO and Chairwoman at Saghmos Therapeutics, a company which she founded that is focused on the prevention of contrast-induced acute kidney injury. She is also the founder and Managing Partner since 2004 of Primary i-Research, LLC, where she provides due diligence to leading healthcare investment funds and evaluates investment prospects of biopharmaceutical companies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, Dr. Kazanchyan has been an Executive Advisor to CEOs of biopharmaceutical companies (start-ups to global companies) on clinical development, regulatory and commercial strategy, as well as business development and valuation. Previously, she was SVP, Business Development and Product Development at Ovid Therapeutics, a company focused on rare neurological disorders. Dr. Kazanchyan was also a Senior Biotechnology Analyst at Wachovia Securities, and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup. She currently serves on the board of directors of Innovate Biopharmaceuticals (Nasdaq: INNT). Dr. Kazanchyan received an M.D. from Harvard Medical School and a B.A. in biology, summa cum laude, from Clark University.
Member of the Compensation Committee
Tony Bruno has been a member of the company’s board of directors since November 2018. Mr. Bruno is a highly accomplished senior pharmaceutical executive with broad expertise in the legal, business development, and corporate development functions within the industry, as well as significant experience in product licensing and M&A transactions. He has spent over 30 years in the pharmaceutical industry, most recently serving as a strategic advisor to Foamix from 2014 until 2018. He was employed at Warner Chilcott from 2000 to 2011, most recently as Executive Vice President with responsibility for all business development activities including product acquisitions and divestitures as well as licensing agreements. Prior to this, he served as General Counsel for Warner Chilcott where he was responsible for all legal activities. From 1984 to 2000, Mr. Bruno held several positions of increasing responsibility within Warner Lambert’s legal division, culminating as General Counsel to the company’s pharmaceutical business. Prior to working in the pharmaceutical industry Mr. Bruno began his legal career as an associate with Shearman & Sterling in New York in 1981. He received a J.D. with honors from George Washington Law School and graduated magna cum laude from Syracuse University with a B.A. in Political Science.
Chief Executive Officer
David Domzalski has been a member of the company’s board of directors since January 2018. Mr. Domzalski has served as our Chief Executive Officer since July 2017. Prior to his role as CEO, Mr. Domzalski served as the President of Foamix Pharmaceuticals Inc. (U.S. subsidiary) since joining the company in April 2014. He has 25 years of industry experience, previously holding positions as Vice President Sales and Marketing at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President Sales and Marketing at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
Dr. Aaron Schwartz
Dr. Aharon Schwartz has been a member of the company’s board of directors since November 2014. He had a distinguished career at Teva Pharmaceuticals spanning nearly four decades, where he served in various senior executive positions until his retirement in 2011, with his most recent role being Vice President, Head of Teva Innovative Ventures. From January 2013 through November 2017, he served as a member of the board of directors of Alcobra Ltd. Dr. Schwartz is currently Chairman of the board of BiolineRx Ltd., and a member of the board of directors of Barcode Ltd. Dr. Schwartz received a Ph.D. in organic chemistry from the Weizmann Institute of Science, and a Ph.D. from the Hebrew University of Jerusalem in the history and philosophy of science. He also received an M.Sc. in organic chemistry from Technion, and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem.
Dr. Dalia Megiddo
Member of the Audit Committee
Dr. Dalia Megiddo has been a member of the company’s board of directors since May 2016. She is an experienced life-science and investment professional in the pharmaceutical and healthcare sectors. Dr. Megiddo currently serves as Managing Partner of Expedio Ventures. She previously ran other life science investment funds, including Jerusalem Global Ventures - InnoMed and 7-Health. Dr. Megiddo also co-founded Bioblast-Pharma Ltd. and currently serves as a member of the company’s board of directors. She co-founded and served on the board of directors of Alcobra Ltd. and Chiasma Ltd. Dr. Megiddo holds an M.D. in Medicine from Hebrew University, Jerusalem, and is a licensed specialist in family medicine. She also holds an M.B.A. from the Kellogg Recanati International School of Business (Tel Aviv University and North Western University).
Sharon Barbari has been a member of the company’s board of directors since January 2019. Ms. Barbari has over 40 years of pharmaceutical and biotechnology experience. From 2004 to 2017, she was Chief Financial Officer at Cytokinetics. Ms. Barbari spent four years from 1998 to 2002 in senior financial roles at Gilead Sciences, including CFO. In this position, she led the finance, accounting and information technology functions during a period of significant growth for Gilead. Ms. Barbari was also employed as CFO and SVP of Finance and Administration at InterMune and VP of Strategic Planning at Foote, Cone & Belding Healthcare. She began her career at Syntex Corporation/Roche Pharmaceuticals where she held various roles of increasing responsibility from 1972 to 1996. Ms. Barbari currently serves as a board member for Sonoma Pharmaceuticals, and as a board member for the Association of Bioscience Finance Officers. Previously, she was a board member for Phytogen Life Sciences. In 2017, Ms. Barbari was a recipient of the YWCA Silicon Valley Tribute to Women Awards. She received her B.S. in accounting from San Jose State University.